Alpha Lipoic Acid Dosage for Fatty Liver

Alpha lipoic acid dosage for fatty liver is a topic of growing interest as more people look beyond lifestyle changes for additional support. Alpha lipoic acid (ALA) is a naturally occurring antioxidant available in the UK as an over-the-counter food supplement, and early research suggests it may help reduce liver inflammation and oxidative stress associated with fatty liver disease. However, there is no MHRA-licensed dose or NICE-approved recommendation for its use in this condition. This article explains what the evidence shows, what doses have been studied, potential side effects, and when to speak to your GP.

What is alpha lipoic acid and how might it help a fatty liver?

ALA is a naturally occurring antioxidant that may reduce liver oxidative stress and inflammation in fatty liver disease by neutralising free radicals and supporting mitochondrial function, though evidence remains investigational rather than established clinical practice.

Alpha lipoic acid (ALA) is a naturally occurring antioxidant compound produced in small amounts by the body and found in foods such as spinach, broccoli and red meat. It has been studied for its potential to reduce liver inflammation and oxidative stress associated with fatty liver disease. ALA is both water-soluble and fat-soluble, which means it can act in a wider range of tissues than many other antioxidants.^[3][5] In the UK it is available as an over-the-counter dietary supplement, typically in capsule or tablet form. It is regulated as a food supplement, not as an MHRA-licensed medicine, and manufacturers are not required to demonstrate efficacy or safety to the same standard as pharmaceutical products.^[13]

Fatty liver disease includes non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease, and involves an accumulation of fat within liver cells. You may also see the condition referred to as metabolic dysfunction-associated steatotic liver disease (MASLD) in more recent clinical literature; NICE guidance (NG49) continues to use the term NAFLD, so both terms refer to broadly the same condition. Over time, fat accumulation can trigger oxidative stress and inflammation, potentially progressing to more serious conditions such as non-alcoholic steatohepatitis (NASH), fibrosis or cirrhosis. ALA is thought to help by neutralising free radicals, supporting regeneration of other antioxidants such as vitamins C and E, and supporting mitochondrial function within liver cells, though these mechanisms are based on laboratory and early clinical research rather than established clinical evidence.^[3][5]

ALA may also have a modest effect on insulin sensitivity, which is relevant because insulin resistance is closely linked to NAFLD.^[4][6] However, ALA is a supplement under investigation, not a licensed treatment for fatty liver disease, and its role remains investigational rather than established clinical practice in the UK.

What dose of alpha lipoic acid is used for fatty liver disease?

No officially recommended dose exists; research studies have most commonly used 300 mg to 600 mg per day, with doses up to 1,200 mg used in some trials but associated with greater adverse effects.

There is no officially recommended or licensed dose of alpha lipoic acid for fatty liver disease in the UK. ALA is not authorised by the MHRA as a medicine for this condition, and NICE has not issued guidance on its use for liver disease. The doses used in clinical research studies have varied considerably. Published trials and systematic reviews examining ALA in NAFLD have most commonly used doses in the range of 300 mg to 600 mg per day, sometimes divided into two doses, taken orally for periods of several weeks to months.^[3][6] Some studies have used higher doses of up to 1,200 mg per day, though these are less common in the published literature and are associated with a greater risk of adverse effects.

It is worth noting that the form of ALA used in supplements varies. R-lipoic acid is the biologically active form produced naturally in the body, while many supplements contain a racemic mixture of both R and S forms.^[3] Some research suggests R-lipoic acid may be absorbed more efficiently, though comparative clinical data specifically in liver disease are limited and this claim should be interpreted cautiously.

Because ALA is sold as a food supplement in the UK rather than as a licensed medicine, the dose printed on a supplement label reflects the manufacturer's choice rather than a clinically validated recommendation.^[13] Anyone considering ALA for fatty liver disease should discuss an appropriate dose with their GP or a registered dietitian before starting, rather than self-selecting a dose based on product labelling alone.

What does the current evidence say about ALA and liver health?

Current evidence is preliminary, with small trials suggesting modest reductions in ALT and AST levels, but ALA is not included in NICE guidance and does not replace lifestyle modification as the primary treatment for NAFLD.

The current evidence for alpha lipoic acid in fatty liver disease is preliminary and largely based on small clinical trials and animal studies, meaning firm conclusions cannot yet be drawn. Several randomised controlled trials have examined ALA, often in combination with other antioxidants or lifestyle interventions, and have reported modest improvements in liver enzyme levels, particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as markers of oxidative stress. Systematic reviews and meta-analyses of these trials have suggested that ALA supplementation may reduce ALT and AST levels in people with NAFLD.^[3][6] Some studies have also reported improvements in insulin resistance scores and lipid profiles. However, most of these studies have been small, short in duration and conducted outside the UK, which limits their generalisability to a UK population.

It is important to distinguish between surrogate outcomes and meaningful clinical endpoints. Improvements in liver enzyme levels do not necessarily translate into reduced fibrosis, lower risk of disease progression or resolution of NASH. Imaging or biopsy-confirmed improvements in liver fat content have been less consistently demonstrated across trials.

ALA is not included in any current NICE clinical guideline for the management of NAFLD or alcohol-related liver disease (NICE NG49).^[1] The NHS approach to fatty liver disease centres on lifestyle modification, including weight loss, dietary change and increased physical activity, alongside management of associated conditions such as type 2 diabetes and dyslipidaemia. ALA should therefore be viewed as a supplement under investigation rather than an evidence-based treatment, and it does not replace established management strategies.

Are there any side effects or safety concerns I should know about?

Common side effects include nausea, gastrointestinal upset, headache, and hypoglycaemia; rare but serious risks include insulin autoimmune syndrome and thiamine deficiency, particularly in those with alcohol-related liver disease.

Alpha lipoic acid is generally considered well tolerated at doses used in most research studies, but it is not without potential side effects and safety considerations. The most commonly reported adverse effects include:

• Gastrointestinal symptoms: nausea, stomach upset, diarrhoea and a feeling of fullness, particularly when taken on an empty stomach

• Headache and dizziness: reported at higher doses

• Skin reactions: rash or itching in some individuals

• Low blood sugar (hypoglycaemia): ALA may lower blood glucose levels, which is particularly relevant for people with diabetes who are taking insulin or other glucose-lowering medicines.^[4][8] If you have diabetes, discuss ALA with your GP or diabetes team before starting, as more frequent blood glucose monitoring may be needed.

A rare but serious concern is insulin autoimmune syndrome, which can cause recurrent or severe hypoglycaemia. Although uncommon, if you experience repeated or unexplained episodes of low blood sugar while taking ALA, stop taking it and seek medical review promptly.

At very high doses, there have been rare reports of more serious effects including thiamine (vitamin B1) deficiency with prolonged use, and isolated case reports of liver injury, though causality has not always been clearly established.^[11][12] People with a history of thiamine deficiency, including those with alcohol-related liver disease, should exercise particular caution and discuss thiamine supplementation with their clinician if relevant. People with thyroid conditions should be aware that some evidence suggests ALA may affect thyroid hormone levels; if you take levothyroxine, seek advice from your GP or pharmacist before starting ALA.^[10]

ALA is not recommended during pregnancy or breastfeeding due to insufficient safety data. If you experience any unexpected symptoms after starting ALA, stop taking it and contact your GP. Suspected adverse reactions to supplements can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk, which accepts reports from both patients and healthcare professionals.

Can I take alpha lipoic acid alongside other fatty liver treatments?

ALA may interact with diabetes medicines, levothyroxine, and other antioxidants, increasing hypoglycaemia risk; always inform your GP or specialist of any supplements you are taking.

Alpha lipoic acid may interact with several medicines and other supplements, so it is important to consider potential interactions before combining it with other treatments for fatty liver disease or related conditions. The most clinically relevant interactions to be aware of include:

• Diabetes medicines: ALA may enhance the glucose-lowering effect of insulin, metformin and other antidiabetic drugs, increasing the risk of hypoglycaemia. If you take any glucose-lowering medicine, discuss this with your GP or diabetes team before starting ALA, as more frequent blood glucose monitoring may be appropriate.

• Thyroid medicines: some evidence suggests ALA may affect thyroid hormone levels or reduce the absorption of levothyroxine if taken at the same time.^[10] If you take levothyroxine, seek advice from your GP or pharmacist; spacing doses apart is generally advisable, though you should follow any specific guidance from your clinical team.

• Other antioxidant supplements: combining ALA with high-dose vitamin E, vitamin C or other antioxidants is used in some research protocols, but may not always be appropriate without professional guidance.

The evidence for an interaction between ALA and chemotherapy medicines is limited and relates to specific agents in oncology settings. If you are receiving cancer treatment, discuss any supplement use with your oncology team before starting.

For people following NHS-recommended lifestyle interventions for NAFLD, such as a calorie-controlled diet and increased physical activity, ALA is unlikely to interfere directly with these approaches. However, it should not be used as a substitute for these evidence-based strategies. If you are under the care of a hepatologist or gastroenterologist for liver disease, it is essential to inform them of any supplements you are taking, as some may affect liver enzyme results and complicate the interpretation of monitoring tests. Transparency with your clinical team ensures your care remains coordinated and safe.

Should I talk to my GP before starting alpha lipoic acid supplements?

Yes, GP review is strongly advisable before starting ALA, especially if you have fatty liver disease, take prescription medicines, or have diabetes or thyroid disease, as ALA is not risk-free despite being available without a prescription.

Yes, speaking to your GP before starting alpha lipoic acid is strongly advisable, particularly if you have a confirmed diagnosis of fatty liver disease, take prescription medicines, or have other health conditions such as diabetes or thyroid disease. Although ALA is available without a prescription in the UK, this does not mean it is suitable for everyone or free from risk. Your GP can review your current medicines, assess whether ALA is appropriate for you, and help you avoid potentially harmful interactions.

For people with NAFLD, NICE guidance (NG49) recommends risk stratification using blood tests such as the FIB-4 score to assess the likelihood of significant liver fibrosis.^[1] Depending on your result, your GP may arrange further assessment using the Enhanced Liver Fibrosis (ELF) test or refer you to a hepatologist or gastroenterologist. If your liver disease is more advanced, specialist input is important before adding any supplement to your regimen. Your GP may also refer you to a registered dietitian, as dietary improvement and weight management remain the most effective and evidence-based interventions for most people with NAFLD.

If you are considering a broader review of your metabolic health alongside liver disease, an online consultation with a GPhC-registered UK online pharmacy such as Bolt Pharmacy can provide access to prescriber review and pharmacist support as part of a wider health assessment, though any treatment would only be recommended where clinically appropriate.

For urgent concerns about your liver health, contact your GP promptly or call NHS 111 for advice. Symptoms such as new jaundice (yellowing of the skin or eyes), significant abdominal pain, vomiting blood, black or tarry stools, confusion or drowsiness, or rapidly increasing abdominal swelling may indicate a serious complication and should be assessed urgently. If symptoms are severe or rapidly worsening, call 999 or go to your nearest emergency department. These symptoms warrant timely medical assessment and should not be managed with supplements alone.

Scientific References

1. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49).
2. Non-alcoholic fatty liver disease (NAFLD).
3. Effects of alpha-lipoic acid supplementation on patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized clinical trials.
4. Alpha lipoic acid administration improved both peripheral sensitivity to insulin and liver clearance of insulin.
5. α-lipoic acid prevents non-alcoholic fatty liver disease in rats.
6. Clinical effectiveness of α-lipoic acid, myo-inositol and propolis supplementation on metabolic profiles and liver function in obese patients with NAFLD: A randomized controlled clinical trial.
7. Dual Thiol Drug-Induced Insulin Autoimmune Syndrome in a Non-Asian Patient Carrying HLA-DRB1*04:06: A Case Report and Literature Review.
8. Alpha-lipoic acid as a trigger of insulin autoimmune syndrome: Current evidence, a case-based approach, diagnostic pitfalls, and practical management.
9. Hypoglycaemia in a non-diabetic patient due to alpha-lipoic acid-induced insulin autoimmune syndrome with HLA-DRB1*04:03:01G.
10. Levothyroxine: a medicine for an underactive thyroid.
11. How and when to take thiamine.
12. Common questions about thiamine.
13. Change in the classification of certain glucosamine products.

Frequently Asked Questions